About Complex I assembly factor TIMMDC1, mitochondrial
Complex I assembly factor TIMMDC1, mitochondrial (TIMMDC1) is a protein
from Homo sapiens identified by UniProt accession
Q9NPL8, 285 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Complex I assembly factor TIMMDC1, mitochondrial |
|---|
| UniProt accession | Q9NPL8 |
|---|
| Gene | TIMMDC1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 285 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- mitochondrial complex I deficiency · score 0.62
- neurodegenerative disease · score 0.55
- primary biliary cirrhosis · score 0.24
- multiple sclerosis · score 0.21
- biliary liver cirrhosis · score 0.20
- lymphocyte count · score 0.18
- systemic lupus erythematosus · score 0.17
- blood protein measurement · score 0.17
- hypothyroidism · score 0.17
- Thyroid preparation use measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NPL8-F1 | alphafold | PREDICTED | 72.41 | — |
Amino-acid sequence (285 residues)
MEVPPPAPRS FLCRALCLFP RVFAAEAVTA DSEVLEERQK RLPYVPEPYY PESGWDRLRE LFGKDEQQRI SKDLANICKT AATAGIIGWV YGGIPAFIHA KQQYIEQSQA EIYHNRFDAV QSAHRAATRG FIRYGWRWGW RTAVFVTIFN TVNTSLNVYR NKDALSHFVI AGAVTGSLFR INVGLRGLVA GGIIGALLGT PVGGLLMAFQ KYSGETVQER KQKDRKALHE LKLEEWKGRL QVTEHLPEKI ESSLQEDEPE NDAKKIEALL NLPRNPSVID KQDKD
Explore Complex I assembly factor TIMMDC1, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets